Second quarter sales advanced 17% to $42.1 million, including $5.7 million from recently acquired Sierra Scientific Instruments, the firm reports Aug. 12. Given acquired the esophageal diagnostics marketer in March for $35 mil. (1"The Gray Sheet" March 29, 2010). Global sales of Given's PillCam SB 2 small bowel endoscopy capsules were flat, largely due to fewer procedures in the U.S. gastrointestinal market and economic instability in Europe, according to the company. As a result, the firm is now expecting full-year 2010 sales to be on the lower end of its previous $167 million-$174 million guidance. Given noted that it recently held a pre-IDE meeting with FDA regarding its PillCam COLON 2 clinical trial and that it is still planning to initiate a study in the second half of this year comparing the capsule-based system with standard colonoscopy. A 510(k) filing will follow in the second quarter of 2011, according to the company
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.